Literature DB >> 23322143

Hyperuricemia and gout: new concepts in diagnosis and management.

Paul P Doghramji1, Robert L Wortmann.   

Abstract

Gout is a chronic, progressive condition for which hyperuricemia is the primary risk factor. The initial episodes of gout may be brief, only lasting for 3 to 5 days, and patients may experience pain-free intercritical periods that last from months to years. However, as the disease progresses, acute gout flares become more frequent and prolonged (typically lasting ≥ 5-10 days). Chronic gouty arthritis develops, with shorter pain-free intervals; tophi become visible and interarticular joint damage occurs. Patients with advanced gout experience chronic pain and a decreased quality of life. Gout prevalence has increased significantly over time. Despite the increase in the number of gout cases, the disease is often mismanaged, especially in primary care. Hyperuricemia is inadequately controlled as a result of suboptimal dosing with urate-lowering drugs, intolerance to therapy, or poor patient compliance. This review article provides a comprehensive discussion of gout pathophysiology, risk factors, and approaches to treatment that encourage the clinician to appreciate hyperuricemia as a multifaceted disorder and manage the condition optimally.

Entities:  

Mesh:

Year:  2012        PMID: 23322143     DOI: 10.3810/pgm.2012.11.2616

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  12 in total

1.  Gender impact on the correlations between subclinical thyroid dysfunction and hyperuricemia in Chinese.

Authors:  Jianping Zhang; Zhaowei Meng; Qing Zhang; Li Liu; Kun Song; Jian Tan; Xue Li; Qiang Jia; Guizhi Zhang; Yajing He
Journal:  Clin Rheumatol       Date:  2015-01-21       Impact factor: 2.980

Review 2.  Elevated Serum Uric Acid and Cardiovascular Disease: A Review and Potential Therapeutic Interventions.

Authors:  Michael Freilich; Andrew Arredondo; Seyedeh Leila Zonnoor; Isabel M McFarlane
Journal:  Cureus       Date:  2022-03-28

3.  Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.

Authors:  Zancong Shen; Colin Rowlings; Brad Kerr; Vijay Hingorani; Kimberly Manhard; Barry Quart; Li-Tain Yeh; Chris Storgard
Journal:  Drug Des Devel Ther       Date:  2015-07-02       Impact factor: 4.162

4.  Screening and characterization of purine nucleoside degrading lactic acid bacteria isolated from Chinese sauerkraut and evaluation of the serum uric acid lowering effect in hyperuricemic rats.

Authors:  Ming Li; Dianbin Yang; Lu Mei; Lin Yuan; Ao Xie; Jieli Yuan
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

5.  Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study.

Authors:  Zancong Shen; Michael Gillen; Kathy Tieu; Mai Nguyen; Erin Harmon; David M Wilson; Bradley Kerr; Caroline A Lee
Journal:  Drug Des Devel Ther       Date:  2016-10-27       Impact factor: 4.162

6.  The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.

Authors:  Scott Baumgartner; Li-Tain Yeh; Zancong Shen; Bradley Kerr; Kimberly Manhard; Barry Quart
Journal:  J Clin Pharmacol       Date:  2018-05-07       Impact factor: 3.126

7.  Microecological treatment of hyperuricemia using Lactobacillus from pickles.

Authors:  Yuanxun Xiao; Congxin Zhang; Xianli Zeng; Zhichao Yuan
Journal:  BMC Microbiol       Date:  2020-07-06       Impact factor: 3.605

Review 8.  Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response.

Authors:  John K Botson; Herbert S B Baraf; Robert T Keenan; John Albert; Karim R Masri; Jeff Peterson; Christianne Yung; Brigid Freyne; Mona Amin; Abdul Abdellatif; Nehad Soloman; N Lawrence Edwards; Vibeke Strand
Journal:  Curr Rheumatol Rep       Date:  2022-02-15       Impact factor: 4.592

9.  Association of dietary patterns with blood uric acid concentration and hyperuricemia in northern Chinese adults.

Authors:  Meiqi Zhou; Xin Huang; Ruiqiang Li; Zechen Zhang; Limin Zhang; Xian Gao; Hui Yang; Yuxia Ma
Journal:  Nutr J       Date:  2022-06-23       Impact factor: 4.344

10.  Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients.

Authors:  Nermina Ziga-Smajic; Selma Skrbo; Samija Muratovic; Belma Pehlivanovic; Dina Lagumdzija; Naida Omerovic
Journal:  Med Arch       Date:  2020-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.